Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + L-DOS47 + Pemetrexed Disodium |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
L-DOS47 | L DOS47|LDOS47 | CEACAM6 Antibody 3 | L-DOS47 comprises urease linked to a monoclonal antibody that targets CEACAM6, which targets urease to tumors, leading to local conversion of urea to ammonia and increased pH, potentially resulting in cytoxicity in tumor cells (J Thorac Oncol, Vol 12 , Issue 1, S1071-S1072, PMID: 25938892). | |
Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02309892 | Phase I | Carboplatin + L-DOS47 + Pemetrexed Disodium | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | Terminated | USA | 0 |